We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
- Authors
Santos, F P S; Faderl, S; Garcia-Manero, G; Koller, C; Beran, M; O'Brien, S; Pierce, S; Freireich, E J; Huang, X; Borthakur, G; Bueso-Ramos, C; de Lima, M; Keating, M; Cortes, J; Kantarjian, H; Ravandi, F
- Abstract
Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 were seen at the University of Texas-M.D. Anderson Cancer Center (UT-MDACC). Forty-five patients (50%) had a history of myelodysplatic syndrome (MDS), compared with 41% in our control group (patients with other AML subtypes) (P=0.08). Poor-risk cytogenetics were more common in patients with AML-M6 (61% versus 38%, P=0.001). Complete remission rates were 62% for patients with AML-M6, comparing with 58% for the control group (P=0.35). Median disease free survival (DFS) for patients with AML-M6 was 32 weeks, versus 49 weeks for the control group (P=0.05). Median overall survival (OS) of patients with AML-M6 was 36 weeks, compared with 43 weeks for the control group (P=0.60). On multivariate analysis for DFS and OS, AML-M6 was not an independent risk factor. AML-M6 is commonly associated with a previous diagnosis of MDS and poor-risk karyotype. The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors.
- Publication
Leukemia, 2009, Vol 23, Issue 12, p2275
- ISSN
1476-5551
- Publication type
Journal Article
- DOI
10.1038/leu.2009.181